Your browser doesn't support javascript.
loading
The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.
Zheng, Bo; Liu, Xiao-Long; Fan, Rong; Bai, Jian; Wen, Hao; Du, Lu-Tao; Jiang, Guo-Qing; Wang, Chun-Ying; Fan, Xiao-Tang; Ye, Yi-Nong; Qian, Yun-Song; Wang, Ying-Chao; Liu, Gao-Jing; Deng, Guo-Hong; Shen, Feng; Hu, He-Ping; Wang, Hui; Zhang, Qing-Zheng; Ru, Lan-Lan; Zhang, Jing; Gao, Yan-Hang; Xia, Jie; Yan, Hua-Dong; Liang, Min-Feng; Yu, Yan-Long; Sun, Fu-Ming; Gao, Yu-Jing; Sun, Jian; Zhong, Chun-Xiu; Wang, Yin; Kong, Fei; Chen, Jin-Ming; Zheng, Dan; Yang, Yuan; Wang, Chuan-Xin; Wu, Lin; Hou, Jin-Lin; Liu, Jing-Feng; Wang, Hong-Yang; Chen, Lei.
Afiliación
  • Zheng B; National Center for Liver Cancer, Shanghai, PR China.
  • Liu XL; International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, PR China.
  • Fan R; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, PR China.
  • Bai J; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
  • Wen H; Berry Oncology Corporation. Beijing, PR China.
  • Du LT; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Digestive & Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China.
  • Jiang GQ; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, PR China.
  • Wang CY; The Clinical Research Center of Shandong Province for Clinical Laboratory, Jinan, PR China.
  • Fan XT; Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, PR China.
  • Ye YN; Xuzhou Infectious Diseases Hospital, Xuzhou, PR China.
  • Qian YS; Dept of Hepatology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China.
  • Wang YC; The Department of Infectious Disease, the First People's Hospital of Foshan, Foshan City, PR China.
  • Liu GJ; Hepatology Department, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, PR China.
  • Deng GH; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, PR China.
  • Shen F; Berry Oncology Corporation. Beijing, PR China.
  • Hu HP; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, PR China.
  • Wang H; Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, PR China.
  • Zhang QZ; Department of Hepatobiliary Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, PR China.
  • Ru LL; Department of Hepatobiliary Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, PR China.
  • Zhang J; Berry Oncology Corporation. Beijing, PR China.
  • Gao YH; Berry Oncology Corporation. Beijing, PR China.
  • Xia J; Berry Oncology Corporation. Beijing, PR China.
  • Yan HD; The First Hospital of Jilin University, Jilin, PR China.
  • Liang MF; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, PR China.
  • Yu YL; Hepatology Department, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, PR China.
  • Sun FM; The Department of Infectious Disease, the First People's Hospital of Foshan, Foshan City, PR China.
  • Gao YJ; Chifeng Clinical Medical School of Inner Mongolia Medical University, Chifeng, PR China.
  • Sun J; Berry Oncology Corporation. Beijing, PR China.
  • Zhong CX; Xuzhou Infectious Diseases Hospital, Xuzhou, PR China.
  • Wang Y; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
  • Kong F; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
  • Chen JM; Berry Oncology Corporation. Beijing, PR China.
  • Zheng D; The First Hospital of Jilin University, Jilin, PR China.
  • Yang Y; Chifeng Clinical Medical School of Inner Mongolia Medical University, Chifeng, PR China.
  • Wang CX; Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
  • Wu L; Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China.
  • Hou JL; Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU), Ministry of Education, Shanghai, PR China.
  • Liu JF; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, PR China.
  • Wang HY; The Clinical Research Center of Shandong Province for Clinical Laboratory, Jinan, PR China.
  • Chen L; Berry Oncology Corporation. Beijing, PR China. chenlei@smmu.edu.cn hywangk@vip.sina.com drjingfeng@126.com wulin@berryoncology.com jlhousmu@163.com.
Clin Cancer Res ; 27(13): 3772-3783, 2021 07 01.
Article en En | MEDLINE | ID: mdl-33947693
ABSTRACT

PURPOSE:

Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful noninvasive biomarker for cancer. However, the HBV integration and mutation landscape on cfDNA remains unclear. EXPERIMENTAL

DESIGN:

A cSMART (Circulating Single-Molecule Amplification and Resequencing Technology)-based method (SIM) was developed to simultaneously investigate HBV integration and mutation landscapes on cfDNA with HBV-specific primers covering the whole HBV genome. Patients with HCC (n = 481) and liver cirrhosis (LC; n = 517) were recruited in the study.

RESULTS:

A total of 6,861 integration breakpoints including TERT and KMT2B were discovered in HCC cfDNA, more than in LC. The concentration of circulating tumor DNA (ctDNA) was positively correlated with the detection rate of these integration hotspots and total HBV integration events in cfDNA. To track the origin of HBV integrations in cfDNA, whole-genome sequencing (WGS) was performed on their paired tumor tissues. The paired comparison of WGS data from tumor tissues and SIM data from cfDNA confirmed most recurrent integration events in cfDNA originated from tumor tissue. The mutational landscape across the whole HBV genome was first generated for both HBV genotype C and B. A region from nt1100 to nt1500 containing multiple HCC risk mutation sites (OR > 1) was identified as a potential HCC-related mutational hot zone.

CONCLUSIONS:

Our study provides an in-depth delineation of HBV integration/mutation landscapes at cfDNA level and did a comparative analysis with their paired tissues. These findings shed light on the possibilities of noninvasive detection of virus insertion/mutation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus de la Hepatitis B / Carcinoma Hepatocelular / Ácidos Nucleicos Libres de Células / Cirrosis Hepática / Neoplasias Hepáticas / Mutación Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Virus de la Hepatitis B / Carcinoma Hepatocelular / Ácidos Nucleicos Libres de Células / Cirrosis Hepática / Neoplasias Hepáticas / Mutación Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article